| HRA000906
(Controlled Access)
|
In prospective clinical study (ChiCTR1900020990, China), personalized neoantigen vaccine was designed and immunized for 10 HCC patients with high risk of postoperative recurrence in a prime boost schedule. No obvious adverse events were observed during neoantigen vaccinations. After vaccination, 70% patients showed neoantigen specific immune response, and have significantly longer RFS than other 3 patients without neoantigen specific immune response or 14 propensity scores matching patients without neoantigen vaccination. Meanwhile, tumor immunological microenvironment could be turned into hot after receiving neoantigen vaccination. Moreover, tracking personalized neoantigen mutations in ctDNA could provide real-time evaluation of clinical response and reflect potential tumor immune escape in HCC patients during neoantigen vaccination and follow up. |
